UpdatesPlus Nicotinic Receptors - Current Research and Development - February 2009
Order a company subscription now and your organization will receive the next 12 monthly issues of UpdatesPlus
Neuronal nicotinic receptor ligands are fast proceeding through clinical development as exciting candidates for multiple CNS disorders including Alzheimer's disease; Schizophrenia; ADHD; Depression; Pain and Addiction. Now we are seeing the field expand with peripheral nicotinic receptors gaining increasing attention in relation to further indications including various inflammatory conditions
Are you involved in these areas; are you developing a nicotinic receptor ligand? If so UpdatesPlus is for you. This service, brought to you from the pharmaceutical analysts, LeadDiscovery, not only identifies all key breaking research, drug development news and clinical trials in this area, it also analyzes it.
Smoking cessation remains the one approved indication for the only commercially available nicotinic receptor ligand varenicline (Chantix/Champix). Activity around varenicline is therefore crucial for other smoking cessation products in development or on the market and vice versa. From February 2009 onwards therefore a major section has been built into UpdatesPlus which tracks the entire smoking cessation/nicotine addiction arena covering drug development and market activity
Published monthly along with a fully up to date pipeline of nicotinic receptor therapeutics, UpdatesPlus offers a key insight into the strategy and development within the nicotinics arena. Offering an ideal intelligence tool for everyone from brand managers to medical directors and preclinical managers, UpdatesPlus is a must for all involved in this exciting new field of medicine
See December 2007 edition now (free sample copy)
Table of Contents
What's in the February 2009 edition of UpdatesPlus-Nicotinic Receptors?
α7 nicotinic receptors
- Sanofi-aventis pulls the plug on its phase 2 Alzheimer's candidate: Last year Sanofi-aventis suspended its phase 2 Alzheimer’s disease study looking at SSR180711. The candidate has now dropped off the company pipeline for what we believe are toxicity reasons
- Continuing evidence emerges to support the development of α7 ligands for the treatment of rheumatoid arthritis: In the January issue of UpdatesPlus we evaluated proof of concept supporting the development of α7 ligands for the treatment of rheumatoid arthritis. In this issue we discuss further evidence and introduce a novel series of nicotinic agents in development at ReceptoPharm (these candidates are licensing options)
- Inflammatory disease indications for α7 ligands extend to multiple sclerosis: Continuing on an inflammatory theme, data published over the past few weeks extends the possible inflammatory indications of nicotinic receptor ligands to include multiple sclerosis.
- Novel α7* receptor identified: A body of evidence exists to support the concept that β amyloid interacts with α7 ligands contributing to the etiology of Alzheimer's disease. Data has just emerged describing a novel α7 receptor. We discuss how this receptor could represent a new therapeutic target
- Full and up to date pipeline of α7 ligands
α4ß2nicotinic receptors
- What is the future of ABT-894?: NeuroSearch announced in February that ABT-894 did not demonstrate “an adequate” effect in two phase 2 pain studies. The pain programme has, as a result been discontinued; we look into the future of ABT-894 for its other indications
- Advances from Targacept: Targacept is one of the key players in the nicotinics field. The company has just released its Q4 2008 results. We discuss new disclosures made during the company webcast
- Is Pfizer about to turn the tables on varenicline?: Varenicline, better known as the smoking cessation therapy Chantix/Champix has recently received negative attention relating to risk of suicidal ideation. We believe Pfizer may be preparing to turn full circle and open a clinical study to evaluate the anti-depressant efficacy of varenicline
- The identification of a dual cholesterol inhibitor/α4β2 receptor antagonist: We report on the identification of a molecule able to inhibit both cholesterol synthesis and cell cholesterol transport and also to antagonize α4β2 receptors. We believe that this profile may offer significant therapeutic benefit. Find out why.
- Full and up to date α4β2 receptor pipeline
Smoking cessation - Nicotine addiction
- Sales performance in the smoking cessation market: Both GSK and Pfizer, the two largest stakeholders in the smoking cessation arena announced Q4 2008 figures- find out how these companies are performing
- Varenicline and its entry into new territories: Contrasting with the US, Varenicline sales are growing in the rest of the world largely due to entry into new geographies. Entry onto the China market occurred during 2008. Data supporting this market entry has just been published however we believe there are shortcomings in the study design
- Smokeless tobacco products to threaten Pfizer/GSK smoking cessation franchises: Smokeless tobacco products are used by many as an alternative to smoking and even as a means of helping smoking cessation. With continued fears around the safety of Champix/Chantix and current underperformance of the GSK franchise there is considerable opportunity for market growth of smokeless tobacco products. Two of the giants in this market are set to partner in what may be a major promotional offensive
- Study launched to evaluate the efficacy of snus as smoking cessation product: Swedish Match has opened a study to evaluate the efficacy of smokeless tobacco as a smoking cessation product. Read our analysis of this study and find out how it could benefit snus sales.
- Has Novartis run into problems with its smoking cessation vaccine, NIC002: Novartis, under license from Cytos Biotechnology, is developing a therapeutic vaccine NIC002 for the treatment of nicotine addiction. This study is currently in phase 2 development however we believe that the candidate may have encountered some problems.
- Full and up to date pipeline of smoking cessation therapeutics
Pricing & Delivery: UpdatesPlus is available on a subscription basis. A one-off payment will get you the next twelve monthly editions of UpdatesPlus-Nicotinic Receptors plus access to all past editions. UpdatesPlus is available for unlimited use within your company. Delivered in a powerpoint format, UpdatesPlus is both easy to use and also ready for use within a presentation setting
2008 issues:
- January 2008
- February 2008
- March 2008
- April 2008
- May 2008
- June 2008
- July 2008
- August 2008
- September
- October
- November
- December
2009 issues:
- January 2008
About UpdatesPlus: Through DailyUpdates, LeadDiscovery has access to one of the most comprehensive sources of information for the drug development sector. UpdatesPlus takes this information and uses our industrial experience to provide a monthly analysis of breaking activity in selected indications and molecular targets. If this is the first time that you have heard of UpdatesPlus please take a moment to have a look at an example. If you would find such a service of use in your area contact us now.
Other users found this report page using the following search terms: Neuronal Nicotinic Receptors MEM 63908 R4996 ABT-107 TC-5619 EVP-6124 AZD-0328 SSR-180711 gts-21 MEM 3454 R3487 chantix champix Varenicline TC-6499 abt-560 AZD3480 TC-1734 tc-5214 ispronicline abt-894 ABT-089 nicotinic receptors cognition cognitive cias alzheimer amyloid depression smoking cessation alpha7 alpha6 alpha4beta2 nicotinic adhd alzheimers nicotine memory nicotinic receptors neuronal receptor varenicline champix chantix wellbutrin nicotinic receptor receptors neuronal agonist drug abt894 schizophrenia 317538 nicotinic nicotine receptors 2009 receptor sclerosis cessation multiple development smoking
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.